Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum ABSWOBY -6.00%67 EV-to-EBITDA is 13.26 as of Jul. 30, 2026, which is 1% below its 10-year median of 13.36. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $18.40 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 745 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 54.09% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Swedish Orphan Biovitrum AB's enterprise value is $18,021 Mil.
Swedish Orphan Biovitrum AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $1,359 Mil. Therefore, Swedish Orphan Biovitrum AB's EV-to-EBITDA for today is 13.26.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's EV-to-EBITDA or its related term are showing as below:
SWOBY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.27 Med: 13.36 Max: 26.4
Current: 13.76
During the past 13 years, the highest EV-to-EBITDA of Swedish Orphan Biovitrum AB was 26.40. The lowest was 8.27. And the median was 13.36.
SWOBY's EV-to-EBITDA is ranked worse than 54.09% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.91
vs SWOBY: 13.76
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Swedish Orphan Biovitrum AB's PE Ratio (TTM) for today is calculated as:
Swedish Orphan Biovitrum AB's share price for today is $23.50.
Swedish Orphan Biovitrum AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.206.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's EV-to-EBITDA falls into.
Swedish Orphan Biovitrum AB's current Enterprise Value is $18,021 Mil.
Swedish Orphan Biovitrum AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,359 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (SWOBY) has a EV-to-EBITDA of 13.26 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Swedish Orphan Biovitrum AB. This is near median its historical median of 13.36. Over the past decade, Swedish Orphan Biovitrum AB's EV-to-EBITDA has ranged from 8.27 to 26.40. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #403 out of 745 companies in the Drug Manufacturers industry, placing it in the top 54.1%.
Is Swedish Orphan Biovitrum AB's EV-to-EBITDA too high?
Swedish Orphan Biovitrum AB's current EV-to-EBITDA of 13.26 is near median its 10-year median of 13.36. Over the past 10 years, this metric has ranged from a low of 8.27 to a high of 26.40. The Drug Manufacturers industry median EV-to-EBITDA is 12.91. Swedish Orphan Biovitrum AB's value of 13.26 is 2.7% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #403 out of 745 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #403 out of 745 companies for EV-to-EBITDA. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median EV-to-EBITDA is 12.91. Swedish Orphan Biovitrum AB's value of 13.26 is 2.7% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own EV-to-EBITDA has ranged from 8.27 to 26.40 over the past decade. While the company's 10-year median is 13.36 vs. the industry median of 12.91, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.91, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current EV-to-EBITDA of 13.26 is 2.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Swedish Orphan Biovitrum AB. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current EV-to-EBITDA is 13.26, which is near median its own 10-year median of 13.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Modestly Overvalued. The stock's GF Value™ is $18.40, compared to a current price of $23.50 — trading 27.7% above its estimated fair value. The current EV-to-EBITDA is 13.26, which is near median its 10-year median of 13.36 and 2.7% above the Drug Manufacturers industry median of 12.91. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current EV-to-EBITDA is 13.26 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.50 is trading 27.7% above its estimated GF Value™ of $18.40.
GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.
Key valuation signals for SWOBY:
EV-to-EBITDA: 13.26 (near median its 10-year median of 13.36)
GF Value™: $18.40 vs. price of $23.50 (27.7% above fair value)
Industry Position: 2.7% above the Drug Manufacturers median (#403 of 745)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
